Document Detail


Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction.
MedLine Citation:
PMID:  15516858     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The benefit of beta blockade has been well established in acute myocardial infarction for several decades, and its benefit in chronic heart failure has been proven since the early 1990's. Several large retrospective analyses suggested the benefit of beta blockers in post-MI systolic dysfunction. Only recently has the benefit of beta blockers been proven in addition to ACE inhibitors, antiplatelet agents, and reperfusion therapy. In the year 2000, CAPRICORN became the first randomized trial to directly address beta blockade in patients with post-infarction systolic dysfunction. The trial showed a 23% reduction in all-cause mortality with carvedilol, in patients already receiving ACE inhibitors, antiplatelet agents, and reperfusion therapy. This is a review of the literature on the administration of beta blockade in patients after acute myocardial infarction with left ventricular systolic dysfunction, as well as a comment on other current treatment modalities for this subset of patients.
Authors:
Emil Thattassery; Mihai Gheorghiade
Related Documents :
2670218 - Ace inhibitors in hypertension: a us perspective.
22833598 - Aspirin administration by emergency medical dispatchers using a protocol-driven aspirin...
21282198 - Salvianolic acid b and tanshinone iia attenuate myocardial ischemia injury in mice by n...
22127378 - Adverse response to cardiac resynchronisation therapy in patients with septal scar on c...
2670218 - Ace inhibitors in hypertension: a us perspective.
9508228 - The relationship between cardiothoracic ratio and left ventricular ejection fraction in...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Heart failure reviews     Volume:  9     ISSN:  1382-4147     ISO Abbreviation:  Heart Fail Rev     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-11-01     Completed Date:  2006-08-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9612481     Medline TA:  Heart Fail Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  107-13     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Northwestern University Feinberg School of Medicine, 33 West Ontario, #25G Chicago, IL 60610, USA. Emil_thattassery@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Clinical Trials as Topic
Heart Failure / drug therapy*,  physiopathology*
Humans
Myocardial Infarction / drug therapy*,  physiopathology*
Systole / drug effects
Ventricular Dysfunction, Left / drug therapy*,  physiopathology
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  B-type natriuretic Peptide and the right heart.
Next Document:  The effects of beta blockers on morbidity and mortality in heart failure.